Table 1.
Summary of pre-treatment characteristics for study participants commencing afatinib.
| Characteristic | Total No. 1151 |
|---|---|
| Age (years) | 60 (52–68) |
| Sex | |
| Male | 443 (38%) |
| Female | 708 (62%) |
| Race | |
| Asian | 839 (73%) |
| White | 299 (26%) |
| Other | 13 (1%) |
| ECOG PS | |
| 0 | 385 (33%) |
| 1 | 726 (63%) |
| 2 | 40 (3%) |
| Prior EGFR inhibitor | 479 (42%) |
| Prior chemotherapy | 595 (52%) |
| Afatinib starting dose | |
| 40 mg | 498 (43%) |
| 50 mg | 653 (57%) |
| Weight (kg) | |
| Median (IQR) | 61 (53–70) |
| Missing | 3 (<1%) |
| Body mass index (kg/m2) | |
| Median (IQR) | 23 (21–26) |
| Missing | 10 (1%) |
| Body surface area (m2) | |
| Median (IQR) | 1.7 (1.5–1.8) |
| Missing | 10 (1%) |
| eGFR (mL/min/1.73 m2) | |
| Median (IQR) | 91 (76–109) |
| Missing | 5 (<1%) |
| Hemoglobin (g/L) | |
| Median (IQR) | 128 (117–138) |
| Missing | 5 (<1%) |
ECOG PS: Eastern Cooperative Oncology Group performance status; eGFR: Estimated glomerular filtration rate; IQR: interquartile range.